| First Author | Ang ES | Year | 2011 |
| Journal | FEBS Lett | Volume | 585 |
| Issue | 17 | Pages | 2755-62 |
| PubMed ID | 21835177 | Mgi Jnum | J:175237 |
| Mgi Id | MGI:5285017 | Doi | 10.1016/j.febslet.2011.07.046 |
| Citation | Ang ES, et al. (2011) Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-kappaB and ERK activation. FEBS Lett 585(17):2755-62 |
| abstractText | Osteolytic bone diseases including osteoporosis are commonly accompanied with enhanced osteoclast formation and bone resorption. Naringin, a natural occurring flavonoid has been found to protect against retinoic acid-induced osteoporosis and improve bone quality in rats. Here, we showed that naringin perturbs osteoclast formation and bone resorption by inhibiting RANK-mediated NF-kappaB and ERK signaling. Naringin suppressed gene expression of key osteoclast marker genes. Naringin was found to inhibit RANKL-induced activation of NF-kappaB by suppressing RANKL-mediated IkappaB-alpha degradation. In addition, naringin inhibited RANKL-induced phosphorylation of ERK. This study identifies naringin as an inhibitor for osteoclast formation and bone resorption, and provides evidence that natural compounds such as naringin might be beneficial as an alternative medicine for the prevention and treatment of osteolysis. |
